Compare Fabrinet (FN) vs HCA Health Inc (HCA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs HCA Health Inc — how do they compare? Fabrinet trades at $500 (market cap $17.46B), while HCA Health Inc trades at $443.69 (market cap $96.35B). The key difference: HCA Health Inc is far larger — about 5.5× Fabrinet's market cap, and HCA Health Inc pays a 0.7% dividend while Fabrinet pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fabrinet for 30 Days and HCA Health Inc for 76 Days on average.
| FN | HCA | |
|---|---|---|
Market Cap | $17.46B | $96.35B |
Volume | 1,199,886 | 1,079,453 |
Sector | Technology | Health |
52-Week High | $746.47 | $545.13 |
52-Week Low | $361.94 | $361.32 |
Typical Hold Time | 30 Days | 76 Days |
Enterprise Value | $16.59B | $146.88B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $497.99, up 1.81% today, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals, including a 45% year-over-year revenue growth in Q4 2026 and consistent earnings beats, driven by surging AI data center demand. Valuation ratios like P/E of 37.34 and P/S of 3.81 reflect high growth expectations. Recent news highlights capacity expansion and AI-driven growth, though high RSI levels suggest potential overbought conditions.
The outlook for FN is positive, with a consensus price target of $769.50 implying significant upside. Key opportunities include AI infrastructure demand and operational leverage, but risks involve customer concentration, margin pressure from high spending, and insider selling. Investors should weigh strong growth prospects against valuation and execution risks in a competitive sector.
HCA Healthcare (HCA) trades at $439.17, up 1.61% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $75.6B in 2025, and has beaten EPS estimates for three consecutive quarters. Analyst consensus is bullish with a $461.12 price target, supported by solid cash flow from operations of $12.64B and a net income margin of 8.77%.
The outlook remains positive given earnings momentum and operational efficiency, but risks include ongoing legal investigations and high debt levels. Upside potential exists if the company maintains its earnings beat streak and manages payer-mix challenges effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →
